U.S. markets closed

Harrow Health, Inc. (HROW)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.14-0.14 (-1.92%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close7.28
Bid6.29 x 900
Ask12.00 x 900
Day's Range7.06 - 7.31
52 Week Range5.40 - 12.99
Avg. Volume128,208
Market Cap193.002M
Beta (5Y Monthly)0.90
PE Ratio (TTM)N/A
EPS (TTM)-0.78
Earnings DateAug 08, 2022 - Aug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for HROW

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Harrow Health, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/29/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • Business Wire

    Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States

    NASHVILLE, Tenn., June 24, 2022--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) of recently acquired, FDA-approved ophthalmic medicines, IOPIDINE® 1%, MAXITROL® 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5%. Harrow also announced that IOPIDINE 1% and MAXITROL are now commercially available; Harrow intends to commercialize MOXEZA 0.5% at a later date. Harrow purchased these medi

  • InvestorPlace

    7 Mighty Micro-Cap Stocks That Could Be Future Moonshots

    Source: iQoncept / Given the way the market’s acting today, now may not seem like the best time to pursue “moonshot” plays. Rising interest rates keep putting pressure on formerly high-flying growth stocks. Meme stocks are struggling to hold onto what’s left of their “to the moon” gains. Yet for investors, there’s an area that may provide such high-risk, high-potential opportunities: micro-cap stocks. Micro-caps, or stocks with market capitalizations under $300 million, are an u

  • Simply Wall St.

    Is Harrow Health, Inc.'s (NASDAQ:HROW) Shareholder Ownership Skewed Towards Insiders?

    Every investor in Harrow Health, Inc. ( NASDAQ:HROW ) should be aware of the most powerful shareholder groups...